Displaying 1 - 2 of 2
| Active Ingredient | EPOIETIN ALPHA |
| Therapeutic Class | HEMATOPOIETIC |
| Indications | Management of symptomatic anaemia associated with chronic renal failure in dialysis and predialysis patients. |
| Caution | Concurrent infection can impair the response to erythropoietin. Aggravation of hypertension (dose-dependent), cardiovascular events, dose-dependent increase in platelet count regressing during treatme More ... |
| Dose Range | Initial dose 50 international units/kg three times weekly, increased at 4-week intervals in increments of 25 units/kg until the target is reached. maintenance 75-300 units/kg once weekly. |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | EPOIETIN BETA |
| Therapeutic Class | HEMATOPOIETIC |
| Indications | Management of symptomatic anaemia associated with chronic renal failure in dialysis and predialysis patients |
| Caution | Concurrent infection can impair the response to erythropoietin. Aggravation of hypertension (dose-dependent), cardiovascular events, dose-dependent increase in platelet count regressing during treatme More ... |
| Dose Range | |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |